The UK's medicines regulator has launched a study to investigate the impact of these drugs following reports of people dying ...

As the NHS rolls out Mounjaro being prescribed by GPs, weight loss jabs have been linked to potentially fatal side effects in new data ...

Weekly injections of the GLP-1 receptor agonist exenatide (Byetta, Bydureon) did not slow Parkinson's disease progression or improve symptoms, the phase III Exenatide-PD3 trial showed. At 96 weeks ...

FRIDAY, Feb. 7, 2025 (HealthDay News) -- The glucagon-like peptide-1 receptor agonist exenatide does not yield improvement in ...

Exenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is currently approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

A study in the United Kingdom involved 194 people with Parkinson’s disease who were randomly assigned to inject themselves once a week with exenatide, marketed as Byetta, or with a placebo.

Vivani Medical has commenced the first-in-human, randomised trial, LIBERATE-1, by initiating screening and enrolment to assess the pharmacokinetic and safety profile of its exenatide NanoPortal ...

While exenatide has been associated with certain side effects including changes in kidney function, low blood sugar, and inflammation of the pancreas, it is a significant addition to Amneal's ...

Second, Amneal has received approval from the FDA for exenatide, which is the Company’s first generic injectable glucagon-like peptide-1 (GLP-1) agonist and reflects its innovation capabilities ...

BRIDGEWATER, N.J., November 21, 2024--Amneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist ...

A large-scale clinical trial found that intravenous infusion of exenatide, a glucagon-like peptide-1 (GLP-1) analog medication, during heart surgeries involving bypass did not significantly reduce ...